Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sanofi - American Depositary Shares
(NQ:
SNY
)
46.30
+1.16 (+2.58%)
Streaming Delayed Price
Updated: 1:54 PM EDT, Mar 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi - American Depositary Shares
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
41
42
Next >
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat
↗
October 25, 2024
The company also hiked its profit outlook for the year and expects single-digit growth.
Via
Investor's Business Daily
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
↗
October 25, 2024
Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat estimates, reaching €13.44 billion, up 12.3%.
Via
Benzinga
Markets Mixed Again; DECK, SKX Beat After The Bell
↗
October 25, 2024
Over the past week or so of trading, we’ve seen the stock market begin to snarl at current valuation levels.
Via
Talk Markets
Sanofi's Earnings Outlook
↗
October 24, 2024
Via
Benzinga
Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business
↗
October 21, 2024
Sanofi and private equity firm CD&R are in negotiations to sell a 50% stake in Opella, Sanofi's consumer healthcare division. With a €16B valuation, Opella is the third-largest player in the global OTC...
Via
Benzinga
This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip?
↗
October 21, 2024
Let's look beyond this piece of bad news from regulators.
Via
The Motley Fool
NASDAQ:SNY is probably undervalued for the fundamentals it is displaying.
↗
October 03, 2024
SANOFI-ADR (NASDAQ:SNY) is an undervalued gem with solid fundamentals.
Via
Chartmill
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer
↗
October 18, 2024
Novartis' Kisqali receives a positive recommendation from EMA's CHMP for adjuvant treatment of early breast cancer, showing a significant reduction in cancer recurrence in a Phase 3 trial. European...
Via
Benzinga
France's PAI Partners Ups Bid for Sanofi's Consumer Health Division As French Government Hints Possible Regulatory Block
↗
October 18, 2024
Sanofi is in talks with CD&R to sell a 50% stake in its consumer healthcare unit, Opella. PAI Partners raised its bid by 200 million euros as the French government weighs the sale due to national...
Via
Benzinga
Sanofi Might Face Political Hurdles In $16B Consumer Pharma Unit Sale To US Private Equity CD&R
↗
October 15, 2024
France considers blocking Sanofi's $16 billion consumer division sale to U.S. firm CD&R, citing concerns over healthcare sovereignty, job protection, and local production amidst growing political...
Via
Benzinga
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
↗
October 11, 2024
Sanofi is negotiating a potential sale of a 50% stake in its consumer health unit, Opella, to Clayton Dubilier & Rice. The deal, valued at $16.4 billion, could help Sanofi sharpen its focus on...
Via
Benzinga
Denali Therapeutics Stock Is Sliding After The Bell: Here's Why
↗
October 10, 2024
Denali Therapeutics shares are moving lower in Thursday's after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued.
Via
Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
↗
October 07, 2024
Via
Benzinga
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
↗
October 07, 2024
These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead.
Via
The Motley Fool
Topics
Artificial Intelligence
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
↗
October 04, 2024
The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5...
Via
Benzinga
Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati
↗
October 04, 2024
Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes milestone payments and is expected to close by the end of 2024.
Via
Benzinga
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
↗
October 04, 2024
Thermo Fisher's Greenville facility, one of the largest in the U.S., has faced repeated FDA regulatory violations. Key concerns include contamination prevention and inadequate equipment sterilization...
Via
Benzinga
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
↗
October 01, 2024
HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket...
Via
Benzinga
Topics
Economy
Week In Review: Zenas Raises $259 Million In IPO
↗
September 28, 2024
It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259...
Via
Talk Markets
Topics
Initial Public Offering
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
↗
September 27, 2024
The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating significant reductions in exacerbations and improved lung function in Phase 3...
Via
Benzinga
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
↗
September 27, 2024
The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD.
Via
Investor's Business Daily
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
September 27, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
September 27, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
↗
September 25, 2024
Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts to...
Via
Benzinga
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
↗
September 25, 2024
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent...
Via
Benzinga
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
↗
September 25, 2024
Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks...
Via
Benzinga
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
September 24, 2024
Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now?
Via
MarketBeat
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
↗
September 23, 2024
Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for Parkinson's disease.
Via
Benzinga
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval
↗
September 23, 2024
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed multiple myeloma patients ineligible for stem cell transplants. Sarclisa is the...
Via
Benzinga
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
↗
September 20, 2024
FTC files a complaint against CVS, Cigna, and UnitedHealth's PBMs, accusing them of inflating insulin prices through a rebate-driven system. The case aims to address unfair practices and improve access...
Via
Benzinga
Topics
Lawsuit
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
41
42
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
